Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
Khouja M, Jiang L, Pal K, Stewart PJ, Regmi B, Schwarz M, Klapper W, Alig SK, Darzentas N, Kluin-Nelemans HC, Hermine O, Dreyling M, Gonzalez de Castro D, Hoster E, Pott C; European Mantle Cell Lymphoma Network. Khouja M, et al. Among authors: pott c. Leukemia. 2024 Dec;38(12):2675-2684. doi: 10.1038/s41375-024-02375-8. Epub 2024 Sep 16. Leukemia. 2024. PMID: 39284897 Free PMC article.
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, Baldus C, Stölzel F. Schroeder T, et al. Among authors: pott c. Intensive Care Med. 2024 Sep;50(9):1459-1469. doi: 10.1007/s00134-024-07576-4. Epub 2024 Aug 22. Intensive Care Med. 2024. PMID: 39172238 Free PMC article. Review.
The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category.
Kotrova M, Fronkova E, Svaton M, Drandi D, Schön F, Hoogeveen P, Hancock J, Skotnicova A, Schilhabel A, Eckert C, Clappier E, Cazzaniga G, Schäfer BW, van Dongen JJM, Ritgen M, Pott C, van der Velden VHJ, Trka J, Brüggemann M. Kotrova M, et al. Among authors: pott c. Leukemia. 2024 Jul;38(7):1617-1620. doi: 10.1038/s41375-024-02265-z. Epub 2024 May 17. Leukemia. 2024. PMID: 38760480 Free PMC article. No abstract available.
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, Eckert C, Fronkova E, Hancock J, Kotrova M, Kraemer R, Montonen M, Pfeifer H, Pott C, Raff T, Trautmann H, Cavé H, Schäfer BW, van Dongen JJM, Trka J, Brüggemann M; EuroMRD Consortium. van der Velden VHJ, et al. Among authors: pott c. Leukemia. 2024 Jun;38(6):1315-1322. doi: 10.1038/s41375-024-02272-0. Epub 2024 May 14. Leukemia. 2024. PMID: 38744919 Free PMC article.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Dreyling M, et al. Among authors: pott c. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2. Lancet. 2024. PMID: 38705160 Free article. Clinical Trial.
246 results